At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
Rasagiline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-week, Three-site, Randomized, Double Blind, Placebo Controlled, Parallel Group, Proof-of-concept Study to Evaluate Rasagiline in the Regional Brain Metabolism on FDG PET in Patients With Mild to Moderate Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating Rasagiline and Placebo for Alzheimer's Disease. Completed, enrolled 50 participants across 3 sites.
Detailed Summary
This is a Phase II, randomized, double blind, placebo controlled, parallel group, proof of concept three-site study, to evaluate the effect of Rasagiline in the regional brain metabolism on 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG-PET).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartMay 2015
Primary CompletionAug 2018
Study CompletionJan 2019
TodayJul 2026
First PostedFeb 10, 2015
Enrollment StartMay 1, 2015
Primary CompletionAug 29, 2018
Study CompletionJan 4, 2019
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 11.4 years ago
Interventions
Rasagilinedrug
Placebodrug